Dopamine receptors: molecular biology, biochemistry and behavioural aspects.
The description of new dopamine (DA) receptor subtypes, D1-(D1 and D5) and D2-like (D2A, D2B, D3, D4), has given an impetus to DA research. While selective agonists and antagonists are not generally available yet, the receptor distribution in the brain suggests that they could be new targets for drug development. Binding characteristics and second messenger coupling has been explored in cell lines expressing the new cloned receptors. The absence of selective ligands has meant that in vivo studies have lagged behind. However, progress has been made in understanding the function of DA-containing discrete brain nuclei and the functional consequence of the DA's interaction with other neurotransmitters. This review explores some of the latest advances in these various areas.
Jackson
D M
DM
Department of Behavioural, Pharmacology, Astra Arcus AB, Södertälje, Sweden.
Westlind-Danielsson
A
A
D000595:Amino Acid Sequence; D000818:Animals; D001923:Brain Chemistry; D002375:Catalepsy / Q000139:chemically induced; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology*; D008969:Molecular Sequence Data; D018377:Neurotransmitter Agents / Q000378:metabolism; D009714:Nucleus Accumbens / Q000187:drug effects; D011954:Receptors, Dopamine / Q000737:chemistry / Q000235:genetics / Q000502:physiology; D015290:Second Messenger Systems; D017557:Ventral Tegmental Area / Q000187:drug effects
D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D018377:Neurotransmitter Agents; D011954:Receptors, Dopamine; D004298:Dopamine